Skip to content
Imuran, Jayempi(azathioprine)
Imuran, Jayempi (azathioprine) is a small molecule pharmaceutical. Azathioprine was first approved as Imuran on 1982-01-01. It is used to treat crohn disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and thrombocytopenic purpura idiopathic amongst others in the USA. It has been approved in Europe to treat graft rejection.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
digestive system diseasesD004066
nervous system diseasesD009422
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
immune system phenomenaD055633
Trade Name
FDA
EMA
Imuran (generic drugs available since 1995-03-31, discontinued: Imuran)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Azathioprine
Tradename
Company
Number
Date
Products
IMURANSebela PharmaceuticalsN-016324 RX1982-01-01
1 products, RLD, RS
Show 1 discontinued
Azathioprine sodium
Tradename
Company
Number
Date
Products
IMURANCasper PharmaN-017391 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
azasanANDA2020-07-01
azathioprine sodiumANDA2023-05-15
imuranNew Drug Application2019-03-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
crohn diseaseEFO_0000384D003424K50
multiple sclerosisEFO_0003885D009103G35
rheumatoid arthritisEFO_0000685D001172M06.9
systemic lupus erythematosusEFO_0002690D008180M32
thrombocytopenic purpura idiopathicEFO_0007160D016553D69.3
ulcerative colitisEFO_0000729D003093K51
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AX: Other immunosuppressants in atc
— L04AX01: Azathioprine
HCPCS
Code
Description
J7500
Azathioprine, oral, 50 mg
J7501
Azathioprine, parenteral, 100 mg
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAZATHIOPRINE
INNazathioprine
Description
Azathioprine is a thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS. It has a role as an antineoplastic agent, an antimetabolite, an immunosuppressive agent, a prodrug, a carcinogenic agent, a DNA synthesis inhibitor and a hepatotoxic agent. It is a thiopurine, a C-nitro compound, a member of imidazoles and an aryl sulfide.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2[nH]cnc12
Identifiers
PDB—
CAS-ID446-86-6
RxCUI1256
ChEMBL IDCHEMBL1542
ChEBI ID2948
PubChem CID2265
DrugBankDB00993
UNII IDMRK240IY2L (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000225201NUDT15, 415C>T, Arg139Cysdrug response2021-03-241A
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 46,395 documents
View more details
Safety
Black-box Warning
Black-box warning for: Azasan, Imuran
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2 adverse events reported
View more details